セッション情報

ポスター

第58回・2020年・京都
ポスター
ポスター
Liver/Immunotherapy
開催回
第58回・2020年・京都

A global study to evaluate TACE in combination with durvalumab (D) ± bevacizumab (B) in patients (pts) with locoregional HCC (EMERALD-1)

演題番号 : P-524

Masatoshi Kudo:1、Bruno Sangro:2、Shukui Qin:3、Zhenggang Ren:4、Stephen Chan:5、Joseph Erinjeri:6、Yasuaki Arai:7、Philip He:8、Shethah Morgan:8、Gordon Cohen:8、Riccardo Lencioni:9

1:Kindai University, Osaka、2:Liver Unit,Clínica Universidad de Navarra and CIBEREHD, Pamplona、3:Department of Medical Oncology,PLA Cancer Center & Bayi Clinical Trial Institute、4:Zhongshan Hospital, Fudan University、5:Department of Clinical Oncology,The Chinese University of Hong Kong、6:Memorial Sloan Kettering Cancer Center、7:National Cancer Center, Tokyo、8:AstraZeneca、9:University of Pisa School of Medicine

A global study to evaluate TACE in combination with durvalumab (D) ± bevacizumab (B) in patients (pts) with locoregional HCC (EMERALD-1)

Durvalumab (D) with or without bevacizumab (B) as adjuvant therapy for patients (pts) with hepatocellular carcinoma (HCC) at risk of recurrence after curative therapy: EMERALD-2

演題番号 : P-525

Jennifer Knox:1、Riccardo Lencioni:2、Ann-Lii Cheng:3、Sean Cleary:4、Peter Galle:5、Norihiro Kokudo:6、Joong-Won Park:7、Jian Zhou:8、Philip He:9、Shethah Morgan:9、Gordon Cohen:9、Jia Fan:8

1:Princess Margaret Cancer Centre,University of Toronto、2:University of Pisa School of Medicine、3:National Taiwan University、4:Mayo Clinic, Rochester、5:University Medical Center Mainz、6:National Center for Global Health and Medicine, Tokyo、7:National Cancer Center, Gyeonggi-do、8:Zhongshan Hospital,Fudan University、9:AstraZeneca

Durvalumab (D) with or without bevacizumab (B) as adjuvant therapy for patients (pts) with hepatocellular carcinoma (HCC) at risk of recurrence after curative therapy: EMERALD-2